INNOVIVA, INC. Available-for-sale Securities, Fair Value Disclosure (Deprecated 2013-01-31)
INNOVIVA, INC. (INVA) had Available-for-sale Securities, Fair Value Disclosure (Deprecated 2013-01-31) of $526.78 million as of 2013-06-30, per its 10-Q filed 2013-08-01.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesFairValueDisclosure · last filed 2013-08-01
- 2013-06-30: Available-for-sale Securities, Fair Value Disclosure (Deprecated 2013-01-31) $526.78M.
- 2013-03-31: Available-for-sale Securities, Fair Value Disclosure (Deprecated 2013-01-31) $550.30M.
- 2012-12-31: Available-for-sale Securities, Fair Value Disclosure (Deprecated 2013-01-31) $335.96M.
- 2012-09-30: Available-for-sale Securities, Fair Value Disclosure (Deprecated 2013-01-31) $358.99M.
| Period end | Available-for-sale Securities, Fair Value Disclosure (Deprecated 2013-01-31) |
|---|---|
| 2013-06-30 | $526.78M 10-Q · filed 2013-08-01 |
| 2013-03-31 | $550.30M 10-Q · filed 2013-05-01 |
| 2012-12-31 | $335.96M 10-Q · filed 2013-08-01 |
| 2012-09-30 | $358.99M 10-Q · filed 2012-10-31 |
| 2012-06-30 | $377.49M 10-Q · filed 2012-08-01 |
| 2011-12-31 | $235.75M 10-K · filed 2013-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |